ACT-01 in Patients With Acute Optic Neuritis

Status:
Recruiting

Trial end date:
2022-12-25

Target enrollment:

Participant gender:

To evaluate the safety and tolerability of ACT-01 compared to placebo in patients with acute optic neuritis (AON) receiving the standard of care.

Phase 2

Accure Therapeutics

Neurotrials